ReviewJournal of diabetes science and technology2009
Ethical issues of predictive genetic testing for diabetes.
Review in Journal of diabetes science and technology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of genetic notification on smoking cessation: systematic review and pooled-analysis.PloS one · 2012Pooled it
- Challenges and Legal Gaps of Genetic Profiling in the Era of Big Data.Frontiers in big data · 2019Article
- Genomic counseling: next generation counseling.Journal of genetic counseling · 2014Article
- Motivations of Patients with Diabetes to Participate in Research.AJOB empirical bioethics · 2014Article
- Nuclear receptor variants in liver disease.Journal of lipids · 2012Article
- Lay perceptions of predictive testing for diabetes based on DNA test results versus family history assessment: a focus group study.BMC public health · 2011Article
- Preferences regarding genetic research results: comparing veterans and nonveterans responses.Public health genomics · 2010Article
- The personalized medicine for diabetes meeting summary report.Journal of diabetes science and technology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the rising number of individuals affected with diabetes and the significant health care costs of treatment, the emphasis on prevention is key to controlling the health burden of this disease. Several genetic and genomic studies have identified genetic variants associated with increased risk to diabetes. As a result, commercial testing is available to predict an individual's genetic risk. Although the clinical benefits of testing have not yet been demonstrated, it is worth considering some of the ethical implications of testing for this common chronic disease. In this article, I discuss several issues that should be considered during the translation of predictive testing for diabetes, including familial implications, improvement of risk communication, implications for behavioral change and health outcomes, the Genetic Information Nondiscrimination Act, direct-to-consumer testing, and appropriate age of testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.